Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Presented for research literature review only Lo HC et al
Pfizer's FY2024 revenue of USD 63.6 billion represents significant decline from its COVID-era peak above USD 100 billion but confirms its standing as a large-scale pharmaceutical company with strong oncology growth (Padcev/enfortumab vedotin, an antibody-drug conjugate, achieved rapid adoption in bladder cancer)
We want to understand exactly what you're hoping to achieve
In contrast, diseases in which there is a prolonged and chronic decrease in glutathione do not respond well to NAC treatment
Supports metabolism and fat burning
US$ 23.67
US$ 21.34
US$ 24.93
US$ 29.53
US$ 25.83
US$ 24.52
US$ 28.77
